Sun Pharmaceutical Industries' Q2 FY 2026-27 Quarterly Results

Result Summary

• Sun Pharmaceutical Industries Ltd reported a 4.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 11.8%.
• Its expenses for the quarter were up by 4.8% QoQ and 14.0% YoY.
• The net profit decreased 31.2% QoQ and decreased 36.2% YoY.
• The earnings per share (EPS) of Sun Pharmaceutical Industries Ltd stood at 8.3 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharmaceutical Industries Ltd, commonly known as Sun Pharma, is a leading pharmaceutical company headquartered in India. The company is primarily engaged in the manufacturing and distribution of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Sun Pharma is one of the largest specialty generic pharmaceutical companies globally, with a strong presence in over 100 countries. The company's diverse product portfolio includes a wide range of branded generics, specialty, over-the-counter products, and APIs. As of the last known updates, Sun Pharma has been focusing on expanding its specialty business, developing innovative products, and enhancing its global reach through strategic acquisitions and partnerships. Notably, the company has been actively involved in research and development to bring new and effective treatments to market. While specific recent developments are not available, these strategic priorities are likely to influence the company's ongoing operations.

Revenue

In Q2FY27, Sun Pharmaceutical Industries Ltd reported a total income of ₹16,716.03 crores, marking a significant increase compared to both the previous quarter (Q1FY27) and the same quarter of the previous year (Q2FY26). The quarter-over-quarter (QoQ) growth in total income was 4.3%, while the year-over-year (YoY) growth was 11.8%. These figures suggest a positive trend in revenue generation for the company, reflecting its ongoing efforts in expanding its market presence and product offerings. The increase in total income can be attributed to various factors, including the company's strategic initiatives, product diversification, and possibly favorable market conditions during this period.

Profitability

Sun Pharma's profitability metrics for Q2FY27 indicate a decline compared to previous periods. The Profit Before Tax (PBT) for the quarter was ₹3,159.37 crores, which represents a decrease of 23.1% from the previous quarter (Q1FY27) and a 24.2% decrease from the same quarter last year (Q2FY26). The Profit After Tax (PAT) for Q2FY27 stood at ₹1,995.07 crores, reflecting a decline of 31.2% QoQ and 36.2% YoY. The reductions in profitability could be influenced by increased total expenses and other operational factors not detailed in the provided data. Additionally, the company's Earnings Per Share (EPS) for the quarter was ₹8.30, down by 31.4% QoQ and 36.2% YoY, aligning with the overall decrease in profitability.

Operating Metrics

The operating metrics for Sun Pharma in Q2FY27 show an increase in total expenses, which amounted to ₹12,287.83 crores. This represents a 4.8% increase QoQ and a 14.0% increase YoY. The rise in expenses is a notable trend, which may impact the company's operating efficiency and profitability. The tax expense for the quarter was ₹1,157.79 crores, showing a slight decrease of 3.3% QoQ but an increase of 12.4% YoY. These figures provide insight into the company's financial management and cost structure during the period, highlighting areas where expenses have risen in relation to income. While the specific causes of these changes are not detailed, they could encompass various operational, strategic, or market-related factors.